Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
Bioengineer
JANUARY 16, 2024
In patients with T790M mutant NSCLC receiving osimertinib, 63% experienced loss of T790M at progression, commonly linked to histological transdifferentiation, KRAS mutations, or gene fusions. not reached) in genomic analysis of post-progression samples from patients receiving second-line osimertinib. months vs. 15.2 months, p = 0.01).
Let's personalize your content